Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Posted on 15 November 2018 | Posted by John Chapman | Posted in Videos, American Heart Association Scientific Sessions 2018

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Latest videos

PlayWhy should clinical practice move to an intensive LDL-C lowering approach?
Chris Packard Why should clinical practice move to an intensive LDL-C lowering approach?
PlayHow do clinicians translate intensive LDL-C lowering to their practice?
Chris Packard How do clinicians translate intensive LDL-C lowering to their practice?
PlayAre very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study
Are very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study
PlayWhich lipid markers best identify residual risk in statin-treated patients?
Which lipid markers best identify residual risk in statin-treated patients?

« Back to videos